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A B S T R A C T
Background: No-reflow phenomenon is a serious complication of primary Percutaneous 
Coronary Intervention (PCI), which may increase the risk of progressive myocardial 
damage, profound left ventricular dysfunction, and death.
Objectives: This study aimed to investigate the incidence of no-reflow phenomenon and 
its clinical, para-clinical, and angiographic determinants in patients who underwent 
primary PCI for ST Elevation Myocardial Infarction (STEMI).
Patients and Methods: This non-randomized prospective cohort study was conducted 
on 397 patients in a cardiovascular tertiary care center in Tehran, Iran from April 2012 to 
April 2014. The inclusion criteria of the study were presenting with acute STEMI of ≤ 12 
h duration or having admitted between 12 and 24 hours after onset with symptoms and 
signs of ongoing ischemia. The participants underwent standard coronary angiography. 
No-reflow phenomenon was defined as a Thrombolysis In Myocardial Infarction (TIMI) 
flow ≤ 2 and no presence of spasm, distal embolization, or dissection after completion of 
the procedure. The association between no-reflow and its determinants was assessed by 
chi-square, student’s t-test, or Mann–Whitney U test. Logistic regression models were 
also used for multivariate analysis. P values < 0.05 were considered to be statistically 
significant.
Results: The participants’ mean (SD) age was of 59 (12.2) years and female/male ratio 
was 83/314. The incidence of no-reflow phenomenon was 63 (15.9%). Besides, the results 
of multivariate analysis showed that only thrombus burden, lesion length, time to 
reperfusion, and type of occlusion had an adjusted association with this phenomenon. 
Conclusions: The study results suggested that no-reflow phenomenon after primary PCI 
would be predictable. Thus, preventive measures, such as using distal protective devices 
or administration of platelet glycoprotein IIb/IIIa antagonists, are advised to be used in 
high-risk patients.
*Corresponding author: Ata Firouzi, Rajaie Cardiovascular Medical and Research 
Center, Vali-e-Asr St., Niayesh Blvd, Tehran, IR Iran. Tel: +98-2123922174, 
Fax: +98-2122663217, 
E-mail: atafirouzi@yahoo.com
1. Background
Nowadays, primary Percutaneous Coronary Intervention 
(PCI) is a gold standard treatment for patients with acute 
ST Elevation Myocardial Infarction (STEMI) (1). Although 
the full patency of the infarct-related artery is achieved 
by primary PCI most of the times, the success rate can 
be reduced if the no-reflow phenomenon occurs (2, 3). 
Thrombolysis In Myocardial Infarction (TIMI) flow 
grade is the most commonly used method for assessment 
of primary PCI success (4). No-reflow phenomenon is a 
serious complication of primary PCI defined as a TIMI 
►Implication for health policy/practice/research/medical education:
Considering the results of this study, cardiologists may be able to predict the occurrence and apply suitable methods for prevention of no-reflow 
phenomenon in patients with STEMI after primary PCI.
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flow ≤ 2 (2, 3). This phenomenon can occur after primary 
PCI in up to one fourths of cases and such patients are 
at an increased risk of progressive myocardial damage, 
profound left ventricular dysfunction, and higher morbidity 
and mortality rates (2, 3, 5-7). Up to now, many studies have 
investigated the pathogenesis and risk factors of no-reflow 
phenomenon (5-10).
2. Objectives
The present study aims to investigate the clinical, 
laboratory, and angiographic predictors of no-reflow 
phenomenon in patients who underwent primary PCI for 
acute STEMI in a tertiary referral cardiovascular center.
3. Patients and Methods
3.1. Study Participants
This non-randomized prospective cohort study was 
conducted in Rajaie Cardiovascular Medical and Research 
Center, the main cardiovascular tertiary care center in 
Tehran, Iran, from April 2012 to April 2014. Totally, 397 
patients admitted in our center with a diagnosis of acute 
STEMI who underwent emergent coronary catheterization 
were consecutively enrolled into the study. According to 
the 2013 ACCF/AHA Guideline for the Management of 
ST-Elevation Myocardial Infarction, “STEMI is a clinical 
syndrome defined by characteristic symptoms of myocardial 
ischemia in association with persistent Electrocardiographic 
(ECG) ST elevation and subsequent release of biomarkers of 
myocardial necrosis” (1). The inclusion criteria of the study 
were presenting with acute STEMI of ≤ 12 h duration or 
having admitted between 12 and 24 hours after onset with 
symptoms and signs of ongoing ischemia. After coronary 
angiography, the patients with coronary vasospasm, less 
than 50% diameter stenosis, and need for emergent/surgical 
revascularization, including left main coronary stenosis 
and any lesions leading to MI on the grafted vessels in the 
patients previously undergone CABG, patients who received 
platelet glycoprotein IIb/IIIa receptor antagonists before 
angiography, and those who were treated with thrombolytic 
therapy, were excluded from the study. The study protocol 
was approved by the research and ethics committee of Rajaie 
Cardiovascular Medical and Research Center.
3.2. Angiography and Primary PCI Procedure
All the patients were treated with 300 milligram (mg) 
aspirin, 600 mg clopidogrel, and 5000 - 10000 units 
unfractionated heparin before transmission to catheterization 
laboratory. Standard left and right coronary angiography 
was performed in all the patients via femoral approach 
using guiding catheter and at least 2 best projections were 
acquired for each patient. The angiograms were assessed and 
quantitative angiographic measurements were done by an 
expert interventional cardiologist and the following findings 
were recorded: Infarct Related Artery (IRA) and its luminal 
diameter, target lesion characteristics (lesion location, lesion 
length, type of occlusion, lesion type in subtotal occlusion, 
and thrombus burden), and initial and post procedural TIMI 
flow grade. Decision to perform primary PCI and to choose 
the optimal PCI technique in each patient was also made by 
the interventional cardiologist after coronary angiography. 
Depending on the lesion characteristics, one of the following 
techniques was used for primary PCI: balloon angioplasty, 
stenting with pre–dilation, and direct stenting with or 
without thrombus suction.
Occlusion was defined as total type if the lesion had an 
abrupt end without tapering and as subtotal if the lesion had 
a tapered end. If the most protruding margin of the lesion 
was located in the outer quarter of the vessel lumen, the 
lesion was defined as subtotal. Besides, the intraluminal 
filling defects that did not have calcification were defined 
as thrombus (9). The thrombus burden of the target lesion 
was assessed according to the TIMI thrombus classification 
(4). “Thrombus burden was classified as mild if consistent 
with TIMI thrombus class 0 and 1, moderate if consistent 
with TIMI thrombus class 2 and 3, and high if the greatest 
linear dimension of the thrombus was more than TIMI 
thrombus class 3” (9).
3.3. Definition of No-Reflow Phenomenon
If TIMI flow ≤ 2 was observed despite successful 
dilatation and there was no spasm, distal embolization, or 
dissection after completion of the procedure, the patient 
was considered to have no-reflow phenomenon.
3.4. Reperfusion Time
Time to reperfusion was defined as the time from the 
onset of symptoms to the first angioplasty balloon inflation. 
Additionally, door to balloon was defined as the time from 
patient’s arrival to the emergency department to the first 
balloon inflation (1).
3.5. Study Variables and Data Collection
The primary outcome of the study was “no-reflow 
phenomenon”. Other variables, including the predictors of 
the no-reflow phenomenon, were measured, as well. Besides, 
demographic data, risk factors of cardiovascular diseases, 
clinical and para-clinical findings, and characteristics of 
the recent MI were extracted from the patients’ medical 
records. Also, angiographic findings, primary PCI findings, 
and characteristics of the target lesion were obtained during 
the angiographic procedure, as explained above.
3.6. Statistical Analysis
All the statistical analyses were performed using the 
IBM SPSS statistical software for Windows, version 19.0 
(IBM Corp., Armonk, NY, USA). Firstly, Kolmogorov-
Smirnov test was used to assess the normal distribution 
of the data. Categorical variables were expressed as 
number and percentage and quantitative ones as mean 
(standard deviation) or median (interquartile range) for 
the variables that did not follow normal distribution. 
Categorical variables were compared by chi-square, 
student t-test, or Mann–Whitney test, as appropriated. In 
addition, binary logistic regression analysis was used for 
multivariate analysis. P values < 0.05 were considered to 
be statistically significant.
4. Results
4.1. Baseline Characteristics
This study was conducted on 397 patients with the mean 
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age of 59 ± 12.2 years (female/male ratio = 83/314). No-
reflow phenomenon was diagnosed in 63 patients (15.9%). 
The patients with and without the no-reflow phenomenon 
were compared regarding the background data, and the 
results have been presented in Table 1. Accordingly, the 
patients in the no-reflow group were older than other 
participants (P < 0.001). The history of MI was also higher 
among these patients (P = 0.001).
4.2. Characteristics of Myocardial Infarction
Some characteristics of MI in our study population have 
been presented in Table 2. Based on the results, there was no 
significant difference between the two groups regarding the 
risk factors of coronary artery disease, history of previous 
MI, and the infarction territory in the current MI and IRA. 
However, time to reperfusion and door to balloon time 
were longer in the no-reflow group (P < 0.001). Except 
for platelet count, inflammatory factors were also higher 
among the patients with the no-reflow phenomenon (P < 
0.001) (Table 2).
4.3. Coronary Angiography Findings
The associations between the incidence of no-reflow 
phenomenon and its determinants evaluated by coronary 
angiography have been presented in Table 3. Except for the 
culprit artery, all the measured factors were significantly 
associated with the no-reflow phenomenon. In the no-reflow 
patients, the target lesion was mainly located in the proximal 
segment of the arteries and occlusion was mainly total and 
with greater lesion length. Thrombosuction was a frequent 
method for reperfusion in these patients. Prescription of GP 
IIb/IIIa inhibitor was also more frequent in the patients with 
no-reflow phenomenon (all P values < 0.001).
4.4. Multivariable Analysis
For assessment of the adjusted associations between 
the no-reflow phenomenon and other predictors detected 
in bivariate analysis, a logistic regression model with 
backward elimination method was applied and the results 
have been presented in Table 4. The results indicated that 
among the several predictors previously mentioned, only 
Table 1. Comparison of the Two Groups Regarding the Baseline Data
Normal Reflow, (n = 334) No-Reflow, (n = 63) P value
Age, years 64 (13.8) 58 (11.6) < 0.001
Gender (F/M) 15/48 68/266 0.3
Hypertension 22 (34.9%) 115 (34.3%) 0.5
Diabetes mellitus 12 (19%) 65 (19.5%) 0.7
Smoking 7 (11.1%) 39 (12%) 0.3
Hyperlipidemia 21 (33.3%) 109 (32.6%) 0.1
Family history 3 (4.7%) 17 (5%) 0.2
History of MI 30 (47.6%) 55 (16.5%) 0.001
Abbreviations: MI, myocardial infarction
* Data presented as mean (SD) and count (%)
Table 2. Myocardial Infarction Characteristics in the Study Groups
No-Reflow, (n = 63) Normal Reflow, (n = 334) P value
MI territory
Anterior 15(23.8%) 62(18.6%)
0.2Inferior 47(74.6%) 253(75.7%)
Posterior 1(1.6%) 19(5.7%)
Time to reperfusion
≤ 2 hours 0(0) 89(26.6)
< 0.0012 - 4 hours 2(3.2) 157(47)
≤ 4 hours 61(96.8) 88(26.3)
Door to balloon
< 30 min 1(1.6%) 129(38.6%)
< 0.00130 - 60 min 19(30.2%) 161(48.2%)
≥ 60 min 43(68.3%) 44(13.2%)
ST segment resolution
≥ 70% 22(34.9%) 264(79%)
< 0.001
< 70% 41(65.1%) 70(21%)
CTnI 33.7(21) 1.8(3) < 0.001
CK-MB 218(106) 45(25.3) < 0.001
WBC count 15800(400) 10300(3023) < 0.001
Platelet count 219000(3000) 219000(66250) 0.3
ESR 63(36) 17(9) < 0.001
hs CRP 29(26) 4(4) < 0.001
Abbreviations: MI, myocardial infarction; CTnI, cardiac troponin I; CK-MB, creatine kinase-MB; WBC, white blood cell; ESR, 
erythrocyte sedimentation rate; hs-CRP, high-sensitivity C-reactive protein
* Data presented as mean ± SD and count (%)
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thrombus burden, lesion length, time to reperfusion, and 
type of occlusion were independently associated with the 
primary endpoint of the study (Table 4).
5. Discussion
The incidence of no-reflow phenomenon has been 
reported to be 5 - 24% in different studies (5-10). In the 
present study, the rate of no-reflow phenomenon following 
the primary PCI was 15.9%, which was similar to other 
studies. This rate was 24.8% in the study by Kirma et al. 
(9) and 9.5% in the one by Du et al. (11).
The results of univariate analysis showed that certain 
factors, such as age, WBC count, hs-CRP level, time 
to reperfusion, door to balloon time, type of occlusion 
(total, subtotal), type of lesion in subtotal occlusions 
(eccentric, concentric), lesion length, lesion location 
(proximal, medial, and distal), thrombus burden, and 
angioplasty technique, could be related to development 
of no-reflow phenomenon. However, time to reperfusion, 
type of occlusion, lesion length, and thrombus burden 
were identified as the independent predictors of no-reflow 
phenomenon in multivariate analysis.
Generally, prompt restoration of antegrade blood flow 
of the coronary artery is critical in treatment of Acute MI 
(AMI). Therefore, primary PCI is superior to thrombolytic 
therapy (1). One of the most important factors related to 
no-reflow phenomenon is the reperfusion time (6-10). In 
the current study, 96.8% of the patients with no-reflow 
phenomenon had a reperfusion time more than 4 hours. 
Previous studies showed that the patients with delayed 
Table 3. Angiographic Findings in the No-Reflow Patients Compared to the Normal Reflow Group
No-Reflow, (n = 63) Normal Reflow, (n = 334) P value
Infarct-related artery
LAD 46 (73%) 254 (76%)
0.5RCA 15 (23.8%) 62 (18.6%)
LCx 2 (3.2%) 18 (5.4%)
Initial TIMI flow
0 56 (88.9%) 72 (21.6%)
< 0.0011 7 (11.1%) 161 (48.2%)
2 0 101 (30.2%)
Target lesion location
Proximal 59 (93.7%) 119 (35.6%)
< 0.001Medial 4 (603%) 169 (50.6%)
Distal 0 46 (13.8%)
Type of occlusion
Subtotal 1 (1.6%) 225 (6704%) < 0.001
Total 62 (98.4%) 109 (32.6%) 0.004
Lesion type in subtotal occlusion
Concentric 32 (50.8%) 105 (31.4%)
< 0.001Eccentric 31 (49.2%) 229 (68.9%)
Lesion length, mm 16 (14 - 18) 8 (6 - 10)
Thrombus burden
Low 0 135 (40.4%)
< 0.001Moderate 1 (1.6%) 185 (55.4%)
High 62 (98.4%) 14 (4.2%)
Method of reperfusion
Balloon angioplasty 0 88 (26.3%)
< 0.001
Direct stenting 1 (1.6%) 138 (41.3%)
Stenting + predilation 0 82 (24.6%)
Thrombosuction 22 (34.9%) 12 (3.6%)
Direct stenting + thrombosuction 10 (15.9%) 2 (0.6%)
Stenting + predilation + thrombosuction 18 (28.6%) 9 (2.7%)
Angioplasty + thrombosuction 12 (19%) 3 (0.9%)
GP IIb/IIIa inhibitor 45 (71.4%) 113 (33.8%) < 0.001
Abbreviations: LAD, left anterior descending; RCA, right coronary artery; LCx, left circumflex artery; GP IIb/IIIa, glycoprotein 
IIb/IIIa
* Data presented as mean (SD) and count (%)
Table 4. Multivariable Analysis to Investigate the Adjusted Associations between No-Reflow Phenomenon and some Predictors
Coefficient (β) P value Odds ratio (CI 95%)
Thrombus burden -5.751 0.003 0.003 (0.001 - 0.135)
Lesion length -0.900 0.021 0.407 (0.189 - 0.875)
Time to reperfusion -4.062 0.046 0.017 (0.001 - 0.931)
Type of occlusion -6.294 0.029 0.002 (0.001 - 0.519)
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reperfusion time (more than 4 hours) had a 1.4 fold increase 
in the rate of no-reflow phenomenon (6-10). These patients 
also had a greater thrombus burden because delayed 
reperfusion causes the thrombus to be more organized 
and these organized intracoronary thrombi are very 
vulnerable to distal embolization during primary PCI. In 
the early stages of AMI, the main structural component 
of thrombus is thrombocyte that lyses more easily. With 
a delayed time to reperfusion, erythrocytes are entrapped 
within the thrombus and make it firmer. Fragmentation of 
these thrombi following balloon dilatation can lead to distal 
embolization. Furthermore, prolonged ischemia can lead to 
alteration in capillary integrity, edema in capillary bed and 
myocardial cells, and polymorphonuclear cell plugging (2, 
3, 8-10). Although the thrombus burden is a very important 
issue in the occurrence of no-reflow phenomenon, this 
phenomenon can occur even in patients with lower burden 
of thrombus if they have a prolonged reperfusion time. 
Prolonged ischemia can destroy the capillary bed and it 
is known that the disruption of the vascular bed is one 
of the key elements in the pathogenesis of the no-reflow 
phenomenon (2, 3, 6, 8-11).
Lesion characteristics have also been considered to be 
an important issue in the no-reflow phenomenon (12). 
The findings of the present study revealed that type of 
occlusion, lesion length, and the thrombus burden were 
independently related to the no-reflow phenomenon. Total 
occlusion may be a sign of prolonged ischemia and a fully 
developed thrombus, and causes lower TIMI flow before 
primary PCI. The TIMI flow before the procedure is one 
of the key factors implicated in the no-reflow phenomenon 
(6-11). In our study, all the patients with the no-reflow 
phenomenon had a TIMI flow < 1 before the procedure 
and 89% showed no antegrade flow (TIMI flow = 0). De 
Luca et al. (8) and Kirma et al. (9) showed in their studies 
that the procedural success for primary PCI was better and 
catheterization complications were lower in the presence of 
higher TIMI flows prior to PCI. In general, good TIMI flow 
prior to PCI is a sign of good patency of the infarct-related 
artery and suggests spontaneous lysis of the thrombus and 
smaller thrombus burden.
Lesion length could show the plaque burden in an 
atherosclerotic artery. Kirma et al. (9) reported that the no-
reflow phenomenon was 5.4 folds higher in the patients with 
lesion lengths above 13.5 millimeters. In our study, 84.1% of 
the patients with no-reflow phenomenon had lesion lengths 
above 13.5 millimeters, which was significantly higher 
compared to those without the no-reflow phenomenon.
Thrombus burden is one of the most important factors 
related to the no-reflow phenomenon. By Intra-Vessel 
Ultrasound (IVUS) studies, Tanaka et al. (12) and Watanabe 
et al. (13) demonstrated a marked relationship between 
the lipid rich plaques and the occurrence of the no-reflow 
phenomenon. In our study, 98.4% of the patients with the 
no-reflow phenomenon had a high thrombus burden, which 
was more prevalent among the patients with prolonged 
reperfusion time. According to Ndrepepa G et al. (10) and 
Zhao et al. (14), thrombus burden is the most important 
predictor of the no-reflow phenomenon. As discussed 
earlier, lesions with higher thrombus burdens are vulnerable 
to distal embolization following balloon predilation.
Generally, AMI can be more complicated and primary 
PCI may be less successful in the elderly mainly because of 
their numerous comorbidities and delay in hospitalization 
(15). In the present study, the patients who had the no-
reflow phenomenon were almost 10 years older than 
those without this phenomenon. Advance age was also an 
independent predictor of the no-reflow phenomenon in the 
research by Kirma et al. (9). They stated that there was an 
increased tendency for distal microembolization during 
primary PCI in the elderly because of their more severe 
and diffuse coronary atherosclerosis and calcification. 
However, we found no independent relationships between 
age and occurrence of the no-reflow phenomenon.
Although the role of inflammatory factors in the no-
reflow phenomenon has been investigated in many studies, 
there is no consensus in this regard. In the study by Du et 
al. (11), both WBC count and hs-CRP were independent 
predictors of the no-reflow phenomenon. However, the 
results of multivariate analysis in our study showed no 
relationships between WBC count and hs-CRP, and no-
reflow phenomenon.
In conclusion, the findings of the present study indicated 
that the no-reflow phenomenon after primary PCI would 
be predictable. Accordingly, the patients with delayed 
reperfusion, higher thrombus burden, and longer and 
totally occluded target lesions were more likely to develop 
the no-reflow phenomenon. Thus, preventive measures, 
such as using distal protective devices or administration of 
platelet glycoprotein IIb/IIIa antagonists, are advised to be 
used in high-risk patients (16, 17). Overall, the study results 
indicated the necessity to perform primary PCI as soon as 
possible and to reduce the reperfusion time as the most 
important preventive measures that should be considered 
in administrative programming for AMI patients.
Acknowledgements
This research project was financially supported by 
Rajaie Cardiovascular Medical and Research Center. The 
authors would like to thank Nasim Naderi and Hooman 
Bakhshandeh for their scientific support.
Authors’ Contribution
Ata Firouzi was the project supervisor and participated in 
developing the research idea, study design, data collection, 
and writing the manuscript. Kamran Aeinfar contributed to 
study design, data collection, and writing the manuscript. 
Hamidreza Sanati, Reza Kiani, and Hossein Shahsavari 
cooperated in data collection and p reparation of the 
manuscript.
Financial disclosure
This article was prepared and published under the technical 
supervision of ATRIA knowledge-based Company.
Funding/Support
The study was approved as a research project in Rajaie 
Cardiovascular Medical and Research Center and the costs 
for laboratory tests and data collection were provided by 
this center.
Aeinfar K et al.
Int Cardiovasc Res J. 2016;10(3)112 
References
1. O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Jr., Chung MK, 
de Lemos JA, et al. 2013 ACCF/AHA guideline for the management 
of ST-elevation myocardial infarction: executive summary: a report 
of the American College of Cardiology Foundation/American 
Heart Association Task Force on Practice Guidelines: developed 
in collaboration with the American College of Emergency Physicians 
and Society for Cardiovascular Angiography and Interventions. 
Catheter Cardiovasc Interv. 2013;82(1):E1-27.
2. Reffelmann T, Kloner RA. The “no-reflow” phenomenon: basic 
science and clinical correlates. Heart. 2002;87(2):162-8.
3. Reffelmann T, Kloner RA. The no-reflow phenomenon: A basic 
mechanism of myocardial ischemia and reperfusion. Basic Res 
Cardiol. 2006;101(5):359-72.
4. Gibson CM, de Lemos JA, Murphy SA, Marble SJ, McCabe CH, 
Cannon CP, et al. Combination therapy with abciximab reduces 
angiographically evident thrombus in acute myocardial infarction: 
a TIMI 14 substudy. Circulation. 2001;103(21):2550-4.
5. Brosh D, Assali AR, Mager A, Porter A, Hasdai D, Teplitsky I, 
et al. Effect of no-reflow during primary percutaneous coronary 
intervention for acute myocardial infarction on six-month mortality. 
Am J Cardiol. 2007;99(4):442-5.
6. Hong YJ, Jeong MH, Choi YH, Ko JS, Lee MG, Kang WY, et al. 
Predictors of no-reflow after percutaneous coronary intervention for 
culprit lesion with plaque rupture in infarct-related artery in patients 
with acute myocardial infarction. J Cardiol. 2009;54(1):36-44.
7. Resnic FS, Wainstein M, Lee MK, Behrendt D, Wainstein RV, 
Ohno-Machado L, et al. No-reflow is an independent predictor 
of death and myocardial infarction after percutaneous coronary 
intervention. Am Heart J. 2003;145(1):42-6.
8. De Luca G, van ‘t Hof AW, de Boer MJ, Ottervanger JP, Hoorntje 
JC, Gosselink AT, et al. Time-to-treatment significantly affects the 
extent of ST-segment resolution and myocardial blush in patients 
with acute myocardial infarction treated by primary angioplasty. 
Eur Heart J. 2004;25(12):1009-13.
9. Kirma C, Izgi A, Dundar C, Tanalp AC, Oduncu V, Aung SM, et 
al. Clinical and procedural predictors of no-reflow phenomenon 
after primary percutaneous coronary interventions: experience at 
a single center. Circ J. 2008;72(5):716-21.
10. Ndrepepa G, Tiroch K, Keta D, Fusaro M, Seyfarth M, Pache J, et al. 
Predictive factors and impact of no reflow after primary percutaneous 
coronary intervention in patients with acute myocardial infarction. 
Circulation: Cardiovascular Interventions. 2010;3(1):27-33.
11. Du J, Chen S, Wang W, Zhou C, Li G, Huang T, et al. hs-CRP is a 
potential predictor of no-reflow in patients with AMI after emergency 
PCI. Journal of Geriatric Cardiology December. 2008;5(4):217.
12. Tanaka A, Kawarabayashi T, Nishibori Y, Sano T, Nishida Y, Fukuda 
D, et al. No-reflow phenomenon and lesion morphology in patients 
with acute myocardial infarction. Circulation. 2002;105(18):2148-52.
13. Watanabe T, Nanto S, Uematsu M, Ohara T, Morozumi T, Kotani 
J, et al. Prediction of no-reflow phenomenon after successful 
percutaneous coronary intervention in patients with acute 
myocardial infarction: intravascular ultrasound findings. Circ J. 
2003;67(8):667-71.
14. Zhao Y, Chen Y, Tian F, Wang C, Hu S, Wang J, et al. [Predictors 
of the no-reflow phenomenon after primary percutaneous coronary 
intervention for acute myocardial infarction]. Nan Fang Yi Ke Da 
Xue Xue Bao. 2012;32(2):261-4.
15. Singh M, Mathew V, Garratt KN, Berger PB, Grill DE, Bell MR, et 
al. Effect of age on the outcome of angioplasty for acute myocardial 
infarction among patients treated at the Mayo Clinic. Am J Med. 
2000;108(3):187-92.
16. Niccoli G, Kharbanda RK, Crea F, Banning AP. No-reflow: again 
prevention is better than treatment. Eur Heart J. 2010;31(20):2449-55.
17. Niccoli G, Marino M, Spaziani C, Crea F. Prevention and treatment 
of no-reflow. Acute Card Care. 2010;12(3):81-91.
